Ocugen stock gained 3.37 percent on October 6 as Europe expands

Published on 10/07/2026 at 03:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ocugen stock's Q2 loss reached USD 0.07 per share versus USD 0.05 expected. Cash totaled USD 100.4 million on June 30, 2026, extending runway into 2028.

OCGN, US67577C1053, Illustration mit AI erstellt.

Ocugen stock (ISIN US67577C1053) was trading at USD 1.08 on Nasdaq on October 6, 2026, up 3.37 percent, while the biotechnology company expanded its European operating base. According to Yahoo Finance on October 6, Ocugen appointed Jolanda Crombach as general manager of its European affiliate in Amsterdam.

Europe supports three Phase 3 programs

Crombach will build the European team and infrastructure around OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy and OCU410ST for Stargardt disease. The three programs are in Phase 3, with data readouts planned for 2027 and 2028, followed by potential regulatory submissions in Europe, according to Yahoo Finance.

The European move adds commercial infrastructure to a pipeline that remains dependent on clinical and regulatory milestones. The company is therefore building market access capabilities well before potential launches, while the principal value drivers remain trial data and future filings.

Q2 revenue beat contrasts with loss

Ocugen reported USD 1.49 million of Q2 2026 revenue against a USD 0.89 million consensus estimate, but adjusted investor expectations were not met on earnings. The quarterly loss was USD 0.07 per share versus a projected USD 0.05 loss, according to MarketBeat.

Cash, cash equivalents and restricted cash totaled USD 100.4 million on June 30, 2026, after Ocugen completed a USD 130 million convertible notes financing. The figures extend the stated cash runway into 2028, while quarterly operating expenses rose to USD 17.9 million from USD 15.2 million a year earlier, Benzinga reported.

Analysts see a wide valuation gap

MarketBeat lists a Moderate Buy consensus from five analysts, including four Buy ratings and one Sell rating. The average price target is USD 9.50, with a high of USD 11.00 and a low of USD 7.00, placing the published target range well above the October 6 share price.

The next corporate checkpoint is the shareholder vote on authorized capital. According to StockTitan, the special meeting was adjourned to October 26, 2026, to consider an increase of 250,000,000 authorized common shares.

Ocugen stock stays near its yearly low

Ocugen stock was trading at USD 1.08 on Nasdaq on October 6, 2026 at 10:08 a.m. ET. The session range was USD 1.05 to USD 1.12, the 52-week range was USD 0.97 to USD 2.73, volume was 2.39 million shares and market capitalization was USD 364.5 million.